Loading clinical trials...

COMPLETEDNA

Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test

NCT00236171•Technische Universität Dresden

Summary

The purpose of this study is to evaluate the efficacy of the topical therapies Protopic and Advantan as well as their combination against placebo in a Psoriasis Plaque Test

Detailed Description

daily psoriasis plaque tests for two weeks and optical coherence tomography (OCT) and 20-MHz-ultrasound on day 0 and day 11, 10 days post end of treatment and 20 days post end of treatment

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients older than 18 Years
•Negative urine pregnancy test
•Written informed consent
•Good compliance

Exclusion Criteria

•Patients less than 18 years
•Pregnant patients
•Patients with renal insufficiency, liver diseases
•Patients who received systemic antipsoriatic treatment or UV treatment less than 4 weeks prior to study
•Patients who used topical antipsoriatics within two weeks prior to study
•Immunosuppressed Patients

Locations (1)

Technische Universität Dresden

Dresden, Saxony, Germany

Key Dates

Start Date

September 1, 2004

Primary Completion Date

April 1, 2006

Completion Date

June 1, 2010

Last Updated

June 8, 2010

Enrollment

ACTUAL participants

Conditions

Psoriasis Vulgaris

Interventions

Protopic, Advantan

DRUG

Blood and Urine Test

PROCEDURE

coherence tomography

PROCEDURE

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)

NCT04080635

Psoriasis Vulgaris

View study

COMPLETEDPHASE4

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

NCT04340076

PsoriasisPsoriasis Vulgaris

View study

WITHDRAWNNA

Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 8, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test

Inclusion Criteria

Exclusion Criteria

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris

Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP

A Pilot Study to Explore the Role of Gut Flora in Psoriasis

The Mediterranean Diet and Time-Restricted Eating Dietary Interventions for Psoriasis Study